Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_3
3
43%
Ph phase_2
2
29%

Phase Distribution

2

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 33 (42.9%)

Trials by Status

completed343%
terminated343%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_3

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

NCT02596893
terminatedphase_3

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

NCT02641392
completedphase_1

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

NCT02367183
completedphase_2

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02601300
terminatedphase_2

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

NCT02685683
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02596893Phase 3

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Terminated
NCT02641392Phase 3

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Terminated
NCT02367183Phase 1

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Completed
NCT02601300Phase 2

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Completed
NCT02685683Phase 2

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

Terminated
NCT02974322Phase 3

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Withdrawn
NCT02957474Phase 1

A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7